Abstract

PurposeTo compare the distribution of mammographic features among women recalled for further assessment after screening with digital breast tomosynthesis (DBT) versus digital mammography (DM), and to assess associations between features and final outcome of the screening, including immunohistochemical subtypes of the tumour. MethodsThis randomized controlled trial was performed in Bergen, Norway, and included 28,749 women, of which 1015 were recalled due to mammographic findings. Mammographic features were classified according to a modified BI-RADS-scale. The distribution were compared using 95 % confidence intervals (CI). ResultsAsymmetry was the most common feature of all recalls, 24.3 % (108/444) for DBT and 38.9 % (222/571) for DM. Spiculated mass was most common for breast cancer after screening with DBT (36.8 %, 35/95, 95 %CI: 27.2−47.4) while calcifications (23.0 %, 20/87, 95 %CI: 14.6−33.2) was the most frequent after DM. Among women screened with DBT, 0.13 % (95 %CI: 0.08−0.21) had benign outcome after recall due to indistinct mass while the percentage was 0.28 % (95 %CI: 0.20−0.38) for DM. The distributions were 0.70 % (95 %CI: 0.57−0.85) versus 1.46 % (95 %CI: 1.27−1.67) for asymmetry and 0.24 % (95 %CI: 0.16−0.33) versus 0.54 % (95 %CI: 0.43−0.68) for obscured mass, among women screened with DBT versus DM, respectively. Spiculated mass was the most common feature among women diagnosed with non-luminal A-like cancer after DBT and after DM. ConclusionsSpiculated mass was the dominant feature for breast cancer among women screened with DBT while calcifications was the most frequent feature for DM. Further studies exploring the clinical relevance of mammographic features visible particularly on DBT are warranted.

Highlights

  • Mammography is the most common screening tool for breast cancer

  • We observed differences in the distribution of mammographic features for women recalled after screening with digital breast tomosynthesis (DBT) versus digital mammography (DM)

  • Asymmetry was the most common feature of all recalls for DBT and for DM, less frequent for DBT compared to DM

Read more

Summary

Introduction

Mammography is the most common screening tool for breast cancer. Standard digital mammography (DM) has replaced screen-film mammography in the Western part of the world [1, 2]. Digital breast tomosynthesis (DBT) is expected to be the future screening tool for breast cancer [3,4,5]. European studies have reported higher rates of screen-detected breast cancer when comparing. Higher rate of screen-detected breast cancer in DBT is expected to reduce the number of interval cancers the few published studies on interval cancer have lacked statistical power to conclude on this [12,13,14,15,16]. An increased rate of screen-detected cancer, without a simultaneous reduction in interval cancer rate, might indicate that DBT detects small and biologically less aggressive cancers, poten­ tially representing small, low proliferation tumors, which could repre­ sent overdiagnosis and cause overtreatment [13,14]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call